Sūtīt draugam
RSS
google +
Izdrukas variants

Ziņas (Retās slimības)

This section on health in the EU has been created as a trustworthy gateway to a wide range of information and data on health-related issues and activities at both European, national and international level. The content is produced by the European Commission, the Member States of the EU and the European Economic Area (EEA), plus EU candidate countries; by international organisations; and by pan-European non-governmental organisations in the area of public health.

Adamas receives Orphan drug designation for ADS-5102 for treatment of levodopa-induced dyskinesia associated with Parkinson's    epda.eu.com

Adamas Pharmaceuticals, Inc. today announced that the Food and Drug Administration (FDA) has granted orphan drug status to ADS-5102 for the treatment of levodopa-induced dyskinesia associated with Pa[...]

23andMe and Genentech to Analyze Genomic Data for Parkinson's Disease    epda.eu.com

23andMe, Inc., the leading personal genetics company, today announced an agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to generate whole genome sequencing data f[...]

Jinarc recommended for approval in rare kidney disease    europa.eu

Medicine to slow down cyst formation[...]

Zykadia recommended for approval in advanced non small cell lung cancer    europa.eu

Medicine provides treatment option for patients with advanced ALK-positive non-small cell lung cancer previously treated with crizotinib[...]

Rare Disease Day 2015    europa.eu

More medicines becoming available for patients who previously had no treatment options[...]

Use of whole genome sequencing of food-borne pathogens for public health protection    europa.eu

Published on:16 February 2015 Use of whole genome sequencing of food-borne pathogens for public health protection[...]

23andMe and Genentech to Analyze Genomic Data for Parkinson's Disease    epda.eu.com

23andMe, Inc., the leading personal genetics company, today announced an agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to generate whole genome sequencing data f[...]

Record number of medicines for rare diseases recommended for approval in 2014    europa.eu

Number of medicines with new active substances continues to increase[...]

Scientific guideline: Guideline on the use of minimal residue disease as an endpoint in chronic lymphocytic leukaemia studies, draft: consultation open    europa.eu

The scope of this document is to describe the basis and regulatory requirements for the use of minimal residue disease (MRD) as an intermediate endpoint to predict clinical benefit in trials in chron[...]

Regional conference on Rare Diseases (2-3 December 2014, Prague)    europa.eu

The Consumers, Health and Food Executive Agency implements the EU Health Programme, the Consumer Programme and the Better Training for Safer Food initiative[...]

Disclaimer

The European Commission is solely responsible for information present on EU-level websites, information present in the Portal originated by the Commission. National-level information is provided by the Member States concerned and Member States are solely responsible for the accuracy of the information. Likewise, the European Commission is not responsible for information on non-governmental organisations and international organisations websites. The European Union is committed to user privacy. Read more concerning the Legal Notice.
Further questions can be answered through the Contact page. The Health-EU portal supports principles and measures to increase the credibility of information on the net. It complies with the HONcode standard for trustworthy health information: verify here.